Exactech Implant Settlement Results in $8M Payout Over High Failure Rates

Exactech Implant Settlement Results in $8M Payout Over High Failure Rates

Exactech has agreed to pay the U.S. government $8 million to address allegations that it defrauded Medicare and Medicaid by selling defective knee, hip and ankle replacement implants.

The settlement stems from a series of Exactech recalls issued in late 2021 and early 2022, after it was discovered that certain components had been stored in “out-of-specification” vacuum sealed bags, which allowed oxygen to reach the components before they were implanted in patients.

This caused many of the Exactech knee, hip and ankle components to degrade prematurely once implanted in patients, increasing the risk of early failure and the need for risky revision surgery. The recalls impacted Exactech Optetrak, Optetrak Logic and Truliant knee replacement systems, Exactech Vantage ankle systems, and Exactech Novation and Acumatch hip implants.

As a result of the widespread use of the components, the company faced more than 2,500 Exactech lawsuits before declaring Chapter 11 Bankruptcy late last year, resulting in a tentative settlement agreement to resolve both personal injury claims and other liability stemming from the recalls.

In addition to claims brought by individuals who received the defective implants, Exactech also faced charges from the federal government, alleging that the manufacturer violated the Federal False Claims Act “by knowingly submitting or causing the submission of false claims for payment to Medicare, Medicaid, and the United States Department of Veterans Affairs (VA) in connection with defective knee-replacement devices,” according to a Department of Justice press release issued on September 16.

The $8 million settlement agreement was announced on Tuesday, a day after the Delaware bankruptcy court approved the company’s Chapter 11 bankruptcy plans.

The government accused Exactech of knowing as early as January 2006 that certain tibial trays used in knee replacement systems had high failure rates. However, the company continued to market them for surgeries, some of which were performed on beneficiaries for Veterans Affairs, Medicare and Medicaid.

Federal prosecutors also claimed the company knew the polyethylene component in certain Logic and Truliant knee-replacement systems had unacceptable failure rates as early as January 2019, yet continued to let them be implanted into U.S. patients until February 2022.

“Patients who need a medical device to enjoy their lives rely on device manufacturers to put patient safety first. When a manufacturer learns that its device is defective, it must promptly and transparently address the problem.”

– Kelly O. Hayes, U.S. Attorney for the District of Maryland

The Justice Department lawsuit was the result of a qui tam, or whistleblower, lawsuit filed under the False Claims Act by Brooks Wallace, Robert Farley and Dr. Manuel Fuentes who will collectively receive just under $2 million of the settlement deal.

Exactech did not admit to guilt or liability as part of the agreement.


Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.
Plaintiffs involved in GLP-1 vision loss lawsuits are calling for the litigation to be consolidated in New Jersey federal court, and not be bundled with existing stomach paralysis litigation.